



20 November 2019
EMA/HMPC/376416/2019
Committee on Herbal Medicinal Products (HMPC)

European Union herbal monograph on *Achillea millefolium* L., herba

Draft – Revision 1

Initial assessment	
Discussion in Working Party on European Union monographs and European Union list (MLWP)	November 2009 May 2010 July 2010
Adopted by Committee on Herbal Medicinal Products (HMPC) for release for consultation	15 September 2010
End of consultation (deadline for comments)	15 February 2011
Re-discussion in MLWP	March 2011 May 2011
Adoption by HMPC Monograph (EMA/HMPC/290284/2009) Assessment Report (EMA/HMPC/290309/2009) List of references (EMA/HMPC/290282/2009) Overview of comments received during the public consultation (EMA/HMPC/238500/2011) HMPC Opinion (EMA/HMPC/544934/2011)	12 July 2011
First systematic review	
Discussion in HMPC/MLWP	July 2019 September 2019 November 2019
Adopted by HMPC for release for consultation	20 November 2019
Start of public consultation	01 February 2020
End of consultation (deadline for comments). Comments should be provided using this template to hmpc.secretariat@ema.europa.eu .	30 April 2020
Re-discussion in HMPC/MLWP	
Adoption by HMPC	

Keywords	Herbal medicinal products; HMPC; European Union herbal monographs; traditional use; <i>Achillea millefolium</i> L., herba; Millefolii herba; yarrow
----------	---



BG (bulgarski): Бял равнец, стрък	IT (italiano): Achillea millefoglie parti aeree
CS (čeština): Řebříčková nať	LT (lietuvių kalba): Kraujažolių žolė
DA (dansk): Røllike	LV (latviešu valoda): Pelašķu laksti
DE (deutsch): Schafgarbenkraut	MT (Malti): Ғaxixa tal-morliti
EL (elliniká): Πόα αχιλλείας	NL (Nederlands): Duizendblad, kruid
EN (English): yarrow	PL (polski): Ziele krwawnika
ES (español): Milenrama, sumidades floridas de	PT (português): Milefólio
ET (eesti keel): Raudrohuürt	RO (română): Iarbă de coada șoricelului
FI (suomi): Siänkärsämä	SK (slovenčina): Vňat' rebríčka
FR (français): Achillée millefeuille (parties aériennes d')	SL (slovenščina): Zel navadnega rmana
HR (hrvatski): Stolisnikova zelen	SV (svenska): Rölleka, ört
HU (magyar): Közönséges cickafark virágos hajtás	IS (íslenska):
	NO (norsk): Ryllik

European Union herbal monograph on *Achillea millefolium* L., herba

1. Name of the medicinal product

To be specified for the individual finished product.

2. Qualitative and quantitative composition^{1, 1}

Well-established use	Traditional use
	<p>With regard to the registration application of Article 16d(1) of Directive 2001/83/EC</p> <p><i>Achillea Millefolium</i> L., herba (yarrow)</p> <p>i) Herbal substance</p> <p>Not applicable</p> <p>ii) Herbal preparations</p> <p>a) Comminuted herbal substance</p> <p>b) Expressed juice from fresh herb (DER: 1:0.65-0.93)</p> <p>c) Liquid extract (DER 1:1), extraction solvent ethanol 25% V/V</p> <p>d) Tincture (ratio of herbal substance to extraction solvent 1:5), extraction solvent ethanol 45% V/V</p> <p>e) Tincture (ratio of herbal substance to extraction solvent 1:5), extraction solvent ethanol 31.5% V/V</p> <p>f) Dry extract (DER 6-9:1), extraction solvent water</p> <p>g) Dry extract (DER 5-10:1), extraction solvent water</p>

3. Pharmaceutical form

Well-established use	Traditional use
	Comminuted herbal substance as herbal tea for

¹ The declaration of the active substance(s) for an individual finished product should be in accordance with relevant herbal quality guidance.

¹ The material complies with the Ph. Eur. monograph (ref.: 1382).

Well-established use	Traditional use
	<p>oral use.</p> <p>Herbal preparations in liquid or solid dosage forms for oral use.</p> <p>Comminuted herbal substance for infusion preparation for cutaneous use.</p> <p>The pharmaceutical form should be described by the European Pharmacopoeia full standard term.</p>

4. Clinical particulars

4.1. Therapeutic indications

Well-established use	Traditional use
	<p>Indication 1)</p> <p>Traditional herbal medicinal product used for temporary loss of appetite.</p> <p>Indication 2)</p> <p>Traditional herbal medicinal product for the symptomatic treatment of mild, spasmodic gastrointestinal complaints including bloating, and flatulence.</p> <p>Indication 3)</p> <p>Traditional herbal medicinal product for the symptomatic treatment of minor spasm associated with menstrual periods.</p> <p>Indication 4)</p> <p>Traditional herbal medicinal product for the treatment of small superficial wounds.</p> <p>The product is a traditional herbal medicinal product for use in specified indications exclusively based upon long-standing use.</p>

4.2. Posology and method of administration²

Well-established use	Traditional use
	<p>Posology</p> <p><i>Adolescents, adults and elderly</i></p>

² For guidance on herbal substance/herbal preparation administered as herbal tea or as infusion/decoction/macerate preparation, please refer to the HMPC 'Glossary on herbal teas' (EMA/HMPC/5829/2010 Rev.1).

Well-established use	Traditional use
	<p>Single dose</p> <p>Indications 1) and 2)</p> <p>a) Herbal tea: 2-4 g of the comminuted herbal substance in 250 ml boiling water as herbal infusion 3 or 4 times daily between meals.</p> <p>b) Expressed juice: 5-10 ml 2 or 3 times daily.</p> <p>c) Liquid extract: 2-4 ml 3 times daily.</p> <p>d) Tincture (ethanol 45% V/V): 2-4 ml 3 times daily.</p> <p>e) Tincture (ethanol 31.5% V/V): 4.3 ml (= 4.2 g) 4 times daily.</p> <p>For the indication "loss of appetite", the liquid preparations are to be taken 30 minutes before meals.</p> <p>Indication 2)</p> <p>f) Dry extract (DER 6-9: 1), extraction solvent water: 334 mg dry extract 3-4 times daily</p> <p>Indication 3)</p> <p>a) Herbal tea: 1-2 g of the comminuted herbal substance in 250 ml of boiling water as herbal infusion 2-3 times daily.</p> <p>g) Dry extract (DER 5-10: 1), extraction solvent water: 250 mg dry extract 2-3 times daily</p> <p>Indication 4)</p> <p>a) Comminuted herbal substance for infusion preparation for cutaneous use: 3-4 g of the comminuted herbal substance in 250 ml of boiling water 2-3 times daily.</p> <p>The use in children under 12 years of age is not recommended (see section 4.4 'Special warnings and precautions for use').</p> <p>Duration of use</p> <p>Indications 1) and 2)</p> <p>If the symptoms persist longer than 2 weeks during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.</p>

Well-established use	Traditional use
	<p data-bbox="810 255 1066 286">Indications 3) and 4)</p> <p data-bbox="810 315 1410 450">If the symptoms persist longer than 1 week during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.</p> <p data-bbox="810 479 1145 510">Method of administration</p> <p data-bbox="810 533 1114 564">Indications 1), 2) and 3)</p> <p data-bbox="810 593 916 624">Oral use</p> <p data-bbox="810 647 970 678">Indication 4)</p> <p data-bbox="810 707 1426 768">Cutaneous use: to be applied on the affected area in a form of impregnated dressing.</p>

4.3. Contraindications

Well-established use	Traditional use
	<p data-bbox="810 958 1394 1055">Hypersensitivity to the active substances and to other plants of the Asteraceae (Compositae) family.</p>

4.4. Special warnings and precautions for use

Well-established use	Traditional use
	<p data-bbox="810 1249 1426 1310">The use in children under 12 years of age has not been established due to lack of adequate data.</p> <p data-bbox="810 1339 1114 1370">Indications 1), 2) and 3)</p> <p data-bbox="810 1400 1394 1503">If the symptoms worsen during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.</p> <p data-bbox="810 1532 970 1563">Indication 4)</p> <p data-bbox="810 1592 1378 1653">If signs of skin infection are observed, medical advice should be sought.</p> <p data-bbox="810 1682 1426 1854">For tinctures, extracts containing ethanol, the appropriate labelling for ethanol, taken from the 'Guideline on excipients in the label and package leaflet of medicinal products for human use', must be included.</p>

4.5. Interactions with other medicinal products and other forms of interaction

Well-established use	Traditional use
	None reported

4.6. Fertility, pregnancy and lactation

Well-established use	Traditional use
	Safety during pregnancy and lactation has not been established. In the absence of sufficient data, the use during pregnancy and lactation is not recommended. No fertility data available.

4.7. Effects on ability to drive and use machines

Well-established use	Traditional use
	No studies on the effect on the ability to drive and use machines have been performed.

4.8. Undesirable effects

Well-established use	Traditional use
	Hypersensitivity reactions of the skin have been reported. The frequency is not known. If other adverse reactions not mentioned above occur, a doctor or a qualified health care practitioner should be consulted.

4.9. Overdose

Well-established use	Traditional use
	No case of overdose has been reported.

5. Pharmacological properties

5.1. Pharmacodynamic properties

Well-established use	Traditional use
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC.

5.2. Pharmacokinetic properties

Well-established use	Traditional use
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC.

5.3. Preclinical safety data³

Well-established use	Traditional use
	<p>Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC, unless necessary for the safe use of the product.</p> <p>The dry extract (DER 6-9:1; extraction solvent: water) did not reveal mutagenicity in the AMES-test.</p> <p>Adequate tests on reproductive toxicity have not been performed.</p> <p>Tests on carcinogenicity have not been performed.</p>

6. Pharmaceutical particulars

Well-established use	Traditional use
Not applicable	Not applicable

7. Date of compilation/last revision

20 November 2019